Overview

AGBL4 is altered in 0.02% of all cancers with anal squamous cell carcinoma, breast invasive ductal carcinoma, cancer of unknown primary, NOS, esophageal adenocarcinoma, and high-grade glioma, NOS having the greatest prevalence of alterations [3].

The most common alterations in AGBL4 are AGBL4-NTRK2 Fusion (0.04%), AGBL4-ATM Fusion (0.04%), and AGBL4-RAD54L Fusion (0.00%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.